

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



天大藥業有限公司

TIANDA PHARMACEUTICALS LIMITED

(Incorporated in the Cayman Islands with limited liability)

(Stock Code: 00455)

POLL RESULTS OF ANNUAL GENERAL MEETING HELD ON 12 JUNE 2026

POLL RESULTS OF THE AGM

Tianda Pharmaceuticals Limited (the “**Company**”) is pleased to announce the poll results in respect of the resolutions proposed at the annual general meeting of the Company held on 12 June 2026 (the “**AGM**”) as follows:

ORDINARY RESOLUTIONS <small>(NOTE)</small>		Number of Votes (%)	
		For	Against
1.	To receive and consider the audited consolidated financial statements, the report of the Directors and the independent auditor’s report for the year ended 31 December 2025.	1,707,715,358 (100.00%)	0 (0.00%)
2.	(a) To re-elect Mr. FANG Wen Quan as an Executive Director.	1,707,715,358 (100.00%)	0 (0.00%)
	(b) To re-elect Mr. ZHONG Tao as a Non-executive Director.	1,707,715,358 (100.00%)	0 (0.00%)
	(c) To re-elect Mr. ZHU Haomiao as a Non-executive Director.	1,707,715,358 (100.00%)	0 (0.00%)
	(d) To re-elect Mr. CHIU Sung Hong (who has served as an Independent Non-executive Director for more than 9 years) as an Independent Non-executive Director.	1,707,715,358 (100.00%)	0 (0.00%)
	(e) To authorise the Board of Directors to fix the Directors’ remuneration for the year ending 31 December 2026.	1,707,715,358 (100.00%)	0 (0.00%)

ORDINARY RESOLUTIONS ^(NOTE)		Number of Votes (%)	
		For	Against
3.	To re-appoint Ernst & Young as auditor and to authorise the Board of Directors to fix the remuneration of auditor.	1,707,715,358 (100.00%)	0 (0.00%)
4.	To grant a general mandate to the Directors to repurchase shares of the Company (ordinary resolution in item 4 of the notice of the AGM).	1,707,713,358 (99.99%)	2,000 (0.01%)
5.	To grant a general mandate to the Directors to allot, issue and deal with new shares of the Company (ordinary resolution in item 5 of the notice of the AGM).	1,707,715,358 (100.00%)	0 (0.00%)
6.	To extend the general mandate granted to allot, issue and deal with new shares by adding the shares repurchased by the Company (ordinary resolution in item 6 of the notice of the AGM).	1,707,713,358 (99.99%)	2,000 (0.01%)

Note: Please refer to the notice of AGM of the Company dated 30 April 2026 for the full text of the resolutions.

As more than 50% of the votes were cast in favour of each of the above ordinary resolutions numbered 1 to 6, all the ordinary resolutions were duly passed.

As at the date of the AGM, the total number of issued and fully paid up shares of the Company was 2,150,041,884 shares. In relation to all resolutions proposed at the AGM, the total number of shares entitling the holders to attend and vote for or against the resolutions at the AGM was 2,150,041,884 shares. There were no treasury shares held by the Company (including any treasury shares held or deposited with the Central Clearing and Settlement System) nor shares repurchased by the Company pending cancellation. There were no shares entitling the holders to attend and abstain from voting in favour of the resolutions at the AGM as set out in Rule 13.40 of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited and there were no shares requiring the holders to abstain from voting at the AGM under the Listing Rules. There were no shares actually voted but excluded from calculating the poll results.

The AGM was convened by the Board and chaired by Mr. FANG Wen Quan, the Chairman and Managing Director of the Company. All Directors of the Company attended the AGM in person or by electronic means.

Tricor Investor Services Limited, the Hong Kong Branch Share Registrar of the Company, acted as scrutineer for the poll at the AGM.

Shareholders may refer to the circular dated 30 April 2026 (the “**Circular**”) for details of the above resolutions proposed at the AGM. The Circular may be viewed and downloaded from the Company’s website at www.tiandapharma.com or the designated website of The Stock Exchange of Hong Kong Limited at www.hkexnews.hk.

For and on behalf of the Board
Tianda Pharmaceuticals Limited
FANG Wen Quan
Chairman and Managing Director

Hong Kong, 12 June 2026

As at the date of this announcement, the Executive Directors are Mr. FANG Wen Quan (Chairman and Managing Director) and Mr. LUI Man Sang; the Non-executive Directors are Mr. ZHONG Tao and Mr. ZHU Haomiao; and the Independent Non-executive Directors are Mr. LAM Yat Fai, Mr. CHIU Sung Hong and Dr. XIAN Yanfang.